Mixed connective tissue disease: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
No edit summary
imported>Howard C. Berkowitz
No edit summary
Line 1: Line 1:
{{subpages}}
{{TOC|right}}
{{seealso|Scleroderma}}
{{seealso|Scleroderma}}
Now understood to be a distinct disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap (i.e., '''overlap connective tissue disease''') between [[systemic lupus erythematosus]] (SLE), [[scleroderma]], and [[polymyositis]]; a specific subset of  [[scleroderma]] with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity.   
Now often called  distinct [[rheumatology|rheumatologic]] disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap (i.e., '''overlap connective tissue disease''') between [[systemic lupus erythematosus]] (SLE), [[scleroderma]], and [[polymyositis]]; a specific subset of  [[scleroderma]] with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity.  <ref>{{citation
| contribution = Chapter 35: Clinical features of systemic sclerosis
| author = Fredrick M Wigley and Laura K Hummers
| title = Practical Rheumatology
| edition = Third
| publisher = Mosby
| year = 2004
| isbn = 03230299396}}</ref> In [[Medical Subject Headings]], it is termed "A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence." <ref>{{MeSH}}</ref>


Most patients with MCTD have [[autoantibody|autoantibodies]] characteristic of scleroderma, such as [[U1 small nuclear ribonucleoprotein]]s (anti-U1 snRNP OR anti-U1 RNP), and have clinical [[Raynaud's phenomenon]].
Most patients with MCTD have [[autoantibody|autoantibodies]] characteristic of scleroderma, such as [[U1 small nuclear ribonucleoprotein]]s (anti-U1 snRNP OR anti-U1 RNP), and have clinical [[Raynaud's phenomenon]].
==References==
{{reflist}}

Revision as of 07:57, 31 July 2010

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
See also: Scleroderma

Now often called distinct rheumatologic disease, mixed connective tissue disease (MCTD) is variously considered an overlap (i.e., overlap connective tissue disease) between systemic lupus erythematosus (SLE), scleroderma, and polymyositis; a specific subset of scleroderma with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity. [1] In Medical Subject Headings, it is termed "A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence." [2]

Most patients with MCTD have autoantibodies characteristic of scleroderma, such as U1 small nuclear ribonucleoproteins (anti-U1 snRNP OR anti-U1 RNP), and have clinical Raynaud's phenomenon.

References

  1. Fredrick M Wigley and Laura K Hummers (2004), Chapter 35: Clinical features of systemic sclerosis, Practical Rheumatology (Third ed.), Mosby, ISBN 03230299396
  2. Anonymous (2024), Mixed connective tissue disease (English). Medical Subject Headings. U.S. National Library of Medicine.